Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation

Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos Bueso-Ramos, Borje S. Andersson, Chitra M. Hosing, Srdan Verstovsek, Richard E. Champlin, Uday Popat

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received induction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimen was melphalan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4 subsequently relapsed. After a median follow-up of 31 months, 6 patients (49%) survived long term. Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT.

Original languageEnglish (US)
Pages (from-to)555-559
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number4
DOIs
StatePublished - Apr 2010

Keywords

  • Allogeneic stem cell transplantation
  • Leukemic transformation
  • Myelofibrosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation'. Together they form a unique fingerprint.

Cite this